Bernstein Harold, PRES, R, D, CMO, reported an open-market or private sale at Maze Therapeutics, Inc. involving 600.000000 shares for an estimated $26523.00. Reported holdings after the transaction were 14400.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
President, R&D & CMO
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.15 to $44.29 per share, inclusive. The reporting person undertake…
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.20 to $46.19 per share, inclusive.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.20 to $47.17 per share, inclusive.
The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person'…
0 other filings
0 recent txs